569.85
+7.35
(1.31%)
Real-time:
11:54am BST
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | 569.85 - 569.85 |
| 52 week | 380.00 - 575.00 |
| Open | 562.50 |
| Vol. | 614.00 |
| Mkt cap | 50.44M* |
| P/E | - |
| Div/yield | - |
| EPS | -0.01* |
| Shares | 8.85M |
| Beta | - |
| Inst. own | - |
| *GBP |
Events
Mar 26, 2013
Interim 2012 Epistem Holdings PLC Earnings Presentation (London)
Mar 14, 2013
Interim 2012 Epistem Holdings PLC Earnings Release
|
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | -8.16% | -4.39% |
| Operating margin | -11.27% | -15.02% |
| EBITD margin | - | -11.40% |
| Return on average assets | -3.97% | -2.67% |
| Return on average equity | -4.57% | -3.24% |
| Employees | 62 | - |
| Carbon Disclosure Rating | - | - |
Address
48 Grafton Street
MANCHESTER, ENG M13 9XX
United Kingdom - Map
+44-161-6067258 (Phone)
+44-161-6067348 (Fax)
MANCHESTER, ENG M13 9XX
United Kingdom - Map
+44-161-6067258 (Phone)
+44-161-6067348 (Fax)
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
Epistem Holdings Plc is a holding company. The Company is engaged in provision of services to the biotechnology and pharmaceutical industries, covering pre-clinical testing and gene biomarker and diagnostic services and the development of novel therapeutics for partner companies. The trading activity of the Company is principally undertaken in the subsidiary undertaking, Epistem Limited. The Company operates in three segments: Contract Research Services, Personalized Medicine and Novel Therapies. Contract Research Services provides pre-clinical testing services. Personalized Medicine specializes in molecular measures of biological effect and point of care molecular diagnostic testing. Novel Therapies is discovering key regulators of epithelial stem cells.
Officers and directors
| Matthew H. Walls | Chief Executive Officer, Executive Director | |
| H. John J. Rylands | Financial Director, Company Secretary, Executive Director | |
| Catherine Booth Ph.D. | Managing Director - Contract Research Services, Executive Director | |
| Jeffrey Moore Ph.D. | Managing Director - Novel Therapies, Executive Director | |
| David Eric Evans | Non-Executive Chairman of the Board | |
| Roger Lloyd Ph.D. | Non-Executive Director | |
| Robert Nolan Ph.D. | Non-Executive Director |